Agios Pharmaceuticals, Inc. (AGIO)
收市後：
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
版塊: Healthcare
行業: Biotechnology
全職員工: 383
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director | 1.23M | 無 | 1969 |
| Ms. Cecilia Jones | Chief Financial Officer | 403.36k | 無 | 1975 |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 660.33k | 無 | 1978 |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 769.2k | 無 | 1980 |
| Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | 無 | 1949 |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 1946 |
| Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | 無 | 無 | 1953 |
| Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | 無 | 無 | 1956 |
| Dr. Clive Patience Ph.D. | Chief Technical Operations Officer | 無 | 無 | 1964 |
| Mr. Christopher J. M. Taylor | Vice President of Investor Relations & Corporate Communications | 無 | 無 | 無 |
描述
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月29日 止，Agios Pharmaceuticals, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：5；董事會：2；股東權利：7；現金賠償：6。
